Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum‐Based Therapy

ABSTRACT Background Adenoid cystic carcinoma (ACC) is the second most common and treatment‐resistant salivary gland carcinoma (SGC). Although platinum‐based therapies are effective, the efficacy of eribulin, a microtubule inhibitor with an 18% response rate in a Phase II trial involving recurrent/metastatic SGC, in patients with advanced ACC after platinum therapy remains unclear. Methods We retrospectively analyzed 19 patients with unresectable/metastatic ACC treated with platinum‐based therapy between December 2015 and January 2023 at the National Cancer Center Hospital, Japan. Ten patients received eribulin. Results The median age was 61 years. 84% achieved disease control with the first‐line or later platinum‐based therapy (median progression‐free survival [mPFS]: 7.6 months). Second‐line or later eribulin monotherapy yielded a 50% disease control rate, with mPFS of 3.7 months and median overall survival of 41.7 months. The adverse events, predominantly neutropenia, were manageable. Conclusion Eribulin shows promising effects of unresectable/metastatic ACC, offering tolerable adverse events.